How Should a US Core Test Strategy Work for Clinics and Care Networks in 2026?

What a US Core Test Strategy Actually Means

A US core test strategy is an organized method for deciding which diagnostic tests belong on a routine menu, how those tests should be ordered, when results should be reviewed, and how care teams should respond. For a clinic or care network, it is broader than a laboratory catalog: it connects test selection, ordering policy, clinical workflows, patient access, reimbursement, quality measurement, and follow-up. The term can also cause confusion because “core test” may refer to a laboratory-developed test, a core laboratory test panel, or a recurring set of operational software tests. In a care-coordination context, the most useful meaning is a governed set of high-value tests used consistently across defined patient populations.

Also worth reading: What Makes RPM Software for Care Networks Essential for Coordinated Patient Care? · What Can B2B Pulse Monitoring SaaS Do for Care Networks? · How Can HIPAA Scheduling Care Networks Reduce No-Shows?

As of September 25, 2026, the strategy should reflect the US health system’s fragmented combination of federal rules, state licensing, payer coverage, laboratory certification, and local clinical practice. A network might designate tests as universal, population-specific, situational, or restricted. It should not assume that a test is valuable simply because it is accurate or popular. Value depends on clinical usefulness, turnaround time, cost, access, interpretability, and the probability that the result will change management. For getpulse.care, a relevant strategy would identify which patient-pulse signals—such as overdue labs, abnormal results, care gaps, or abnormal vital trends—need review and what action follows.

How to Build the Core Menu

Start with clinical need rather than vendor catalog size. A useful core menu may cover high-volume tests for chronic disease, shared tests used in multiple specialties, time-sensitive tests requiring escalation, and tests that support a defined care pathway. The exact contents depend on the network’s population, setting, and risk contracts. An outpatient primary-care network will need a different core menu from a children's hospital, behavioral-health network, or multi-state renal organization. A prudent design might classify each test by annual utilization, clinical urgency, specimen requirements, result turnaround, total cost, denial rate, and percentage of results requiring follow-up.

The strategy should define the patient populations for whom each test is appropriate. For example, one test may be routine for adults with diabetes but optional for selected younger patients, while another may be reserved for patients meeting defined risk criteria. Evidence-based guidelines can inform this structure, but a network must also account for local disease burden, referral patterns, and payer coverage. The goal is not to force every clinician into one rigid order set. It is to reduce avoidable variation while preserving clinically justified exceptions. A well-governed menu should normally aim for at least 90% appropriate order-set use in mature programs, while leaving an exception path for unusual cases and incomplete documentation.

Linking Tests to Care-Coordination Workflows

A test strategy fails if ordering and result review are designed separately. Each core test needs an owner, expected turnaround, escalation threshold, and documented next step. Routine results may enter the medical record without manual outreach, while abnormal or critical results require a defined queue, acknowledgment time, and resolution record. For a care network, the operating model should distinguish preliminary screening tests from diagnostic confirmation. It should also specify whether a result belongs in the legal medical record, the care-management platform, or both, while applying the minimum-necessary principle for access controls.

Patient communication is part of the strategy, not an administrative afterthought. A clinic may need a call within one business day for a critical result, a message within 24 to 72 hours for a markedly abnormal but noncritical result, and standard portal delivery for a stable result. Those are workflow targets rather than universal clinical rules; actual timing must follow applicable laboratory requirements, clinician judgment, and the nature of the test. As of September 25, 2026, automated routing should be monitored for missed results and duplicate outreach. A system that sends 95% of urgent notifications within the target but loses 2% in an integration is not effective merely because its average dashboard looks good.

Rules, Guidance, and Clinical Judgment

A strong US core test strategy uses rules to make routine decisions predictable, not to replace professional judgment. Hard stops are appropriate when a regulatory, safety, or contractual requirement makes an exception unacceptable. Soft guidance is better where evidence supports one approach but patient circumstances may justify another. Examples include preferred tests for uncomplicated cases, reflex pathways when a screening result is unexpected, and restrictions on repeated testing inside a clinically inappropriate interval. Each rule should identify its source, owner, review date, and exception process.

This distinction matters because excessive standardization can cause harm as well as inconsistency. A blanket rule may miss pregnancy, recent transfusion, medication changes, atypical symptoms, or an important interaction between comorbidities. Conversely, leaving every ordering decision to individual preference can create unnecessary cost and delay. The strategy should therefore track both inappropriate variation and inappropriate rigidity. Clinics should review cases where clinicians overrode the pathway and cases where they followed it without appropriate documentation. A 5% override rate is not inherently bad; it becomes a warning when overrides are neither expected nor reviewed.

Comparison of Core-Test Governance Models

The hybrid model is usually the most practical starting point for a growing care network. It creates a minimum shared menu while allowing selected programs—such as oncology, pediatrics, or occupational health—to maintain specialty-specific pathways. The network can standardize high-risk processes such as critical-result acknowledgment while allowing lower-risk local variation. Over time, the organization can promote a local rule into the core menu if it demonstrates clinical value, adequate volume, stable operations, and acceptable cost. This approach is less dramatic than imposing total uniformity, but it tends to produce more usable clinical systems.

Quality, Safety, and Performance Measures

The strategy needs a measurement framework that tracks more than order volume. A useful scorecard includes percentage of orders using an approved pathway, median and 90th-percentile turnaround times, critical-result acknowledgment within policy, abnormal-result closure, duplicate-test rate, total cost per completed episode, denial rate, and patient access. Quality should also examine whether at-risk patients actually received recommended follow-up. For example, measuring the percentage of critical lab results acknowledged within 60 minutes is less informative if there is no record showing that clinicians acted on the results.

Baselines should be established before major workflow changes. Many networks can aim to reduce avoidable duplicate testing by 10% to 20% over 12 months without restricting clinically necessary care, but the realistic target depends on baseline performance. Turnaround time should be split by test class because a specialized assay and a routine chemistry panel are not comparable. A reasonable dashboard might review results weekly for critical and time-sensitive tests and monthly for broader quality and cost measures. Quarterly governance can then approve changes. Vendors should report raw counts and denominators; a vendor claiming a “40% improvement” is not useful unless the baseline, measurement window, and excluded cases are visible.

Cost, Pricing, and Reimbursement

Cost evaluation should include more than the laboratory’s list price. A network may pay a lower unit price while receiving slower turnaround, more denials, or more follow-up work. The relevant calculation is total cost of a completed care pathway, including specimen collection, testing, interpretation, communication, repeat testing, and downstream treatment. In negotiated contracts, the network should separate professional, technical, and facility components where applicable and confirm expected allowed amounts. Prices vary substantially by assay, location, payer, and volume, so a US-wide dollar figure would be misleading.

A practical purchasing model combines committed access with volume bands. The network can request bundled pricing for core-menu tests, minimum turnaround commitments, transparent denial and resubmission terms, and fees for after-hours or urgent work. It should also price implementation separately from recurring usage, including interface work, clinical training, report mapping, and quality reporting. A low-priced platform may be inexpensive but expensive if staff spend several hours each day reconciling results. Before signing a one- or three-year agreement, a network should model at least low, expected, and high utilization and test how unit price changes at volume thresholds.

Common Mistakes and Better Alternatives

One common mistake is equating a large menu with a strong core strategy. A 500-test catalog can overwhelm clinicians, increase maintenance, and obscure which pathway should be used. A better alternative is a tiered menu with a small default set, specialty extensions, and a controlled request process for uncommon tests. Another mistake is selecting tests only through a vendor committee. Clinicians who collect specimens, interpret results, manage follow-up, and handle patient questions should participate, while compliance and finance leaders address billing and risk.

A second mistake is failing to assign accountability for result closure. Sending a notification is not the same as completing follow-up. Organizations should define who watches the queue on weekends, who covers leave, how duplicate alerts are suppressed, and when escalation reaches a medical director. A third mistake is changing pathways without measuring outcomes. A rule that cuts laboratory spending by 12% but increases overdue follow-up by 5% may be financially attractive in the short term and harmful to patients. Strong governance compares cost with safety and access rather than rewarding one metric in isolation. Finally, the strategy should be scheduled for formal review at least annually and sooner after major regulatory, clinical, or contractual changes.

When to Act and How to Begin

A network should act when variation is material, results are not reliably closed, clinicians lack a clear default pathway, or procurement costs are rising without improved outcomes. Signs of readiness include an executive sponsor, a clinical owner, a laboratory liaison, an operations lead, and access to order and result data. A 90-day discovery phase can document the top 20 tests by utilization and cost, map current ordering and follow-up, identify critical-result delays, and interview frontline staff. The first implementation should focus on one measurable pathway—such as abnormal-result closure for a high-volume chronic-disease population—rather than rebuilding every protocol at once.

By the end of a six-month pilot, the network should have a governed core menu, approved order sets, exception rules, escalation ownership, vendor performance measures, and a cost baseline. Success might include at least 95% of pilot patients receiving the intended test pathway, 90% of critical alerts acknowledged within policy, and a measurable reduction in avoidable duplicate orders. For getpulse.care, the role is not to prescribe medicine or replace the clinical record. It is to coordinate signals, ownership, timing, and reporting so clinics and care networks can operate a consistent US core testing program with fewer missed actions and clearer accountability.